TOVX
Theriva Biologics Inc.
NYSE MKT: TOVX · HEALTHCARE · BIOTECHNOLOGY
$0.36
+8.67% today
Updated 2026-04-30
Market cap
$16.23M
P/E ratio
—
P/S ratio
22.32x
EPS (TTM)
$-2.08
Dividend yield
—
52W range
$0 – $1
Volume
31.8M
Theriva Biologics Inc. (TOVX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $103089.00 | $3.16M | — | — | — | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | +2969.7% | -100.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | $467623.00 | — | — | — | — | $72000.00 | $157000.00 | $245000.00 | $272000.00 | $240000.00 | $201000.00 | $87000.00 | $268000.00 | $135000.00 | $137000.00 | $108000.00 |
| Gross profit | — | — | — | $103089.00 | $2.70M | — | — | — | — | $-72000.00 | $-157000.00 | $-245000.00 | $-272000.00 | $-240000.00 | $-201000.00 | $-87000.00 | $-268000.00 | $-135000.00 | $-137000.00 | $-108000.00 |
| Gross margin | — | — | — | 100.0% | 85.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| R&D | $2.67M | $6.33M | $4.64M | $1.20M | $1.58M | $3.34M | $12.29M | $6.51M | $14.49M | $32.91M | $29.11M | $18.78M | $11.84M | $11.08M | $5.13M | $7.80M | $11.72M | $14.31M | $12.03M | $8.60M |
| SG&A | — | — | — | — | — | — | $5012.00 | $5.07M | $6.01M | $8.07M | $10.14M | $7.47M | $5.73M | $4.38M | $4.82M | $6.47M | $7.00M | $7.16M | $7.40M | $15.45M |
| Operating income | $-4.12M | $-10.14M | $-7.32M | $-3.68M | $-1.58M | $-5.93M | $-17.30M | $-12.34M | $-20.50M | $-40.98M | $-39.25M | $-26.25M | $-17.57M | $-15.66M | $-10.16M | $-14.27M | $-21.58M | $-21.43M | $-26.35M | $-15.02M |
| Operating margin | — | — | — | -3571.2% | -50.1% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA | $-4.07M | $-9.94M | $-6.91M | $-3.34M | $-1.22M | $-7.48M | $-17.22M | $-11.53M | $-20.48M | $-40.91M | $-39.09M | $-26.01M | $-17.30M | $-15.42M | $-9.96M | $-14.19M | $-19.20M | $-21.96M | $-19.29M | $-14.91M |
| EBITDA margin | — | — | — | -3239.4% | -38.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EBIT | $-4.10M | $-10.14M | $-7.32M | $-3.72M | $-1.58M | $-7.68M | $-17.28M | $-11.58M | $-20.50M | $-40.98M | $-39.25M | $-26.25M | $-17.57M | $-15.66M | $-10.16M | $-14.27M | $-19.29M | $-22.09M | $-19.43M | $-15.02M |
| Interest expense | — | — | $13831.00 | $9879.00 | $10108.00 | — | — | — | — | — | — | — | — | — | — | $93000.00 | $430000.00 | — | — | — |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-4.10M | $-9.89M | $-7.21M | $-3.73M | $-1.71M | $-8.15M | $-17.07M | $-12.32M | $-19.78M | $-43.74M | $-27.25M | $-15.17M | $-13.37M | $-15.30M | $-10.04M | $-14.17M | $-19.68M | $-18.35M | $-25.65M | $-25.25M |
| Net income growth (YoY) | — | -141.3% | +27.2% | +48.2% | +54.1% | -376.2% | -109.4% | +27.8% | -60.6% | -121.1% | +37.7% | +44.3% | +11.9% | -14.5% | +34.4% | -41.1% | -38.9% | +6.8% | -39.8% | +1.6% |
| Profit margin | — | — | — | -3619.6% | -54.1% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |